| Autor: |
Lancaster LE; Institutes of Molecular Biology, University of Witten/Herdecke, Stockumer Str. 10, 58448 Witten, Germany., Wintermeyer W, Rodnina MV |
| Jazyk: |
angličtina |
| Zdroj: |
Blood cells, molecules & diseases [Blood Cells Mol Dis] 2007 Jan-Feb; Vol. 38 (1), pp. 15-8. Date of Electronic Publication: 2006 Nov 28. |
| DOI: |
10.1016/j.bcmd.2006.10.006 |
| Abstrakt: |
Colicins are a family of antibacterial cytotoxins produced by Escherichia coli and released into the environment to reduce competition from other bacterial strains. Colicins kill the target cell by a variety of effects that include depolarisation of the cytoplasmic membrane, a non-specific DNase activity, a highly specific RNase activity or by inhibition of murein synthesis. This review summarises some important findings that implicate colicins as potential anti-tumor agents. Colicins appear to inhibit proliferation of tumor cell lines in a colicin-type--and cell line-dependent fashion and are more toxic to tumor cells than to normal cells within the body. This opens a potential for using bacterial colicins in combating cancer and raises a number of questions concerning the mechanism of action of colicins in targeting tumor cells, their specificity and applicability as anti-tumor therapeutics. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect